Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.

Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.

Lantm��nnen AS-Faktor AB, a subsidiary of Lantm��nnen ek f��r, is a Swedish company located in Stockholm that provides scientific and technical research and development services.

Neotope Biosciences Ltd. provides biological research services. The company is headquartered in South San Francisco, CA.

JIMRO Co., Ltd. engages in the manufacture and sales of medical devices. It markets Adacolumn, a company developed therapeutic device that selective absorbs granulocytes and monocytes/ macrophages from the blood, and Percutaneous Transluminal Coronary Angioplasty (PTCA) Baloon Catheter. The company was founded on November 8, 1977 and is headquartered in Takasaki, Japan.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

Shanghai Zhongji Guowei Electronics Co., Ltd. engages in research and development, design, sales, and system integration of integrated circuits, electronic products, and household appliances. Its products include microcontrollers, chips, and modules. The company was founded on December 13, 2007 and is headquartered in Shanghai, China.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Zhuhai Hongke Electronic Technology Co., Ltd., established on 2008-01-24, The scope of business includes the production of electronic products,research and development,Sales;Lighting Accessories,building materials,metallic material(No precious metals),Hardware Accessories,Wholesale of daily necessities,retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.

Anqing Jinke Electronics Co., Ltd., established on 2010-12-02, Business scope includes crystal components,Electronic Component,Electronic instrument development,design,manufacture(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).****